[go: up one dir, main page]

MX2009006306A - Composiciones suplementaria nutricional para el tratamiento de enfermedades oculares. - Google Patents

Composiciones suplementaria nutricional para el tratamiento de enfermedades oculares.

Info

Publication number
MX2009006306A
MX2009006306A MX2009006306A MX2009006306A MX2009006306A MX 2009006306 A MX2009006306 A MX 2009006306A MX 2009006306 A MX2009006306 A MX 2009006306A MX 2009006306 A MX2009006306 A MX 2009006306A MX 2009006306 A MX2009006306 A MX 2009006306A
Authority
MX
Mexico
Prior art keywords
supplement composition
treatment
nutritional supplement
ocular diseases
macular degeneration
Prior art date
Application number
MX2009006306A
Other languages
English (en)
Inventor
Georg Ludwig Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006306(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009006306A publication Critical patent/MX2009006306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un antioxidante y composición de suplemento de luteína, la cual entre otras cosas, reduce la pérdida de agudeza visual reduciendo el riesgo de desarrollar degeneración macular de etapa tardía o relacionada con la edad, en personas con degeneración macular relacionada con la edad temprana.
MX2009006306A 2006-12-15 2007-12-13 Composiciones suplementaria nutricional para el tratamiento de enfermedades oculares. MX2009006306A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (en) 2006-12-15 2006-12-15 Nutritional supplement composition for treatment of ocular diseases
PCT/EP2007/063908 WO2008071775A1 (en) 2006-12-15 2007-12-13 Nutritional supplement composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2009006306A true MX2009006306A (es) 2009-06-23

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006306A MX2009006306A (es) 2006-12-15 2007-12-13 Composiciones suplementaria nutricional para el tratamiento de enfermedades oculares.

Country Status (22)

Country Link
US (1) US20100028459A1 (es)
EP (2) EP1932521A1 (es)
JP (1) JP2010513248A (es)
KR (1) KR20090089473A (es)
CN (1) CN101557807A (es)
AR (1) AR064332A1 (es)
AU (1) AU2007331432A1 (es)
BR (1) BRPI0720046A2 (es)
CA (1) CA2672013A1 (es)
CL (1) CL2007003630A1 (es)
CO (1) CO6220929A2 (es)
EC (1) ECSP099516A (es)
GT (1) GT200900161A (es)
MA (1) MA30994B1 (es)
MX (1) MX2009006306A (es)
NO (1) NO20092633L (es)
PE (1) PE20081580A1 (es)
RU (1) RU2009126735A (es)
TN (1) TN2009000241A1 (es)
TW (1) TW200843725A (es)
WO (1) WO2008071775A1 (es)
ZA (1) ZA200903862B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
US20100159029A1 (en) * 2008-12-23 2010-06-24 Alcon Research, Ltd. Composition and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
WO2013005037A1 (en) * 2011-07-07 2013-01-10 Howard Foundation Holdings Ltd Improvements in or relating to visual performance and/or macular pigmentation
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US9314445B2 (en) * 2011-09-12 2016-04-19 Tassos Georgiou Use of omega fatty acids for treating disease
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔（北京）生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
WO2020109192A1 (en) * 2018-11-27 2020-06-04 Novaliq Gmbh Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
JP2023533633A (ja) * 2020-03-11 2023-08-04 ボシュ ＋ ロム アイルランド リミテッド 超長鎖脂肪酸を含む眼の健康のための組成物および方法
WO2025151943A1 (pt) * 2024-01-18 2025-07-24 Moro Peres Nemecio Suplemento alimentar particularmente indicado para combate da degeneração macular, cápsula compreendendo o dito suplemento e uso do mesmo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
CA2633868A1 (en) * 2005-12-20 2007-07-05 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Also Published As

Publication number Publication date
TW200843725A (en) 2008-11-16
AR064332A1 (es) 2009-04-01
RU2009126735A (ru) 2011-01-20
PE20081580A1 (es) 2009-01-01
CL2007003630A1 (es) 2008-08-08
WO2008071775A1 (en) 2008-06-19
BRPI0720046A2 (pt) 2013-12-24
US20100028459A1 (en) 2010-02-04
CO6220929A2 (es) 2010-11-19
CN101557807A (zh) 2009-10-14
ZA200903862B (en) 2010-05-26
MA30994B1 (fr) 2009-12-01
EP1932521A1 (en) 2008-06-18
CA2672013A1 (en) 2008-06-19
NO20092633L (no) 2009-07-10
EP2094252A1 (en) 2009-09-02
TN2009000241A1 (en) 2010-10-18
ECSP099516A (es) 2009-08-28
GT200900161A (es) 2009-11-30
KR20090089473A (ko) 2009-08-21
AU2007331432A1 (en) 2008-06-19
JP2010513248A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
TN2009000241A1 (en) Nutritional supplement composition for treatment of ocular diseases
MX2009006342A (es) Composicion de complemento alimenticio para tratamiento de enfermedades oculares.
AR034220A1 (es) Complemento nutricional para tratar la degeneracion macular
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
GB201100925D0 (en) Composition and method of manufacture
EP2781899A3 (en) Multi-band color vision filters
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
MY176679A (en) Use of nutritional compositions for preventing disorders
AU2008313418A8 (en) Composition for regulating lipid metabolism
WO2007076416A3 (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
NZ778131A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2008094825A3 (en) Compositions and methods for maintaining, strengthening, improving or promoting eye health
WO2006062716A3 (en) Methods and compositions for treating ocular disorders
WO2007127273A3 (en) Methods and compositions for altering cell function
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
TWI319708B (en) Methods and compositions for altering cell fuction
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
WO2008070169A3 (en) Use of carboxyamidotriazole (cai) orotate in macular degeneration
MY178169A (en) Topical ophthalmic peptide formulation
ECSP13012799A (es) Uso de composiciones nutricionales que incluyen lactoferrinas para mejorar la resistencia a enfermedades y condiciones
WO2011045383A3 (en) 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
WO2012025229A8 (en) Composition and method of manufacture
WO2006117826A3 (en) Composition comprising olive oil enriched and supplemented with lutein

Legal Events

Date Code Title Description
FA Abandonment or withdrawal